News

Published on 10 Aug 2023 on Zacks via Yahoo Finance

Pliant Therapeutics, Inc. (PLRX) Reports Q2 Loss, Misses Revenue Estimates


Article preview image

Pliant Therapeutics, Inc. (PLRX) came out with a quarterly loss of $0.70 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to loss of $0.82 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 4.11%. A quarter ago, it was expected that this company would post a loss of $0.66 per share when it actually produced a loss of $0.67, delivering a surprise of -1.52%.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

NASDAQ.PLRX price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Paradigm Biocapital Advisors LP Acquires New Stake in Pliant Therapeutics Inc

On September 24, 2024, Paradigm Biocapital Advisors LP (Trades, Portfolio) marked a significant p...

GuruFocus.com · via Yahoo Finance 1 Oct 2024

Earnings Preview: Pliant Therapeutics, Inc. (PLRX) Q4 Earnings Expected to Decline

The market expects Pliant Therapeutics, Inc. (PLRX) to deliver a year-over-year decline in earnin...

Zacks via Yahoo Finance 7 Mar 2024

Pliant Therapeutics Inc CFO Keith Cummings Sells 9,781 Shares

Keith Cummings, the CFO of Pliant Therapeutics Inc, sold 9,781 shares of the company on January 1...

GuruFocus.com via Yahoo Finance 22 Jan 2024

Is a Surprise Coming for Pliant Therapeutics (PLRX) This Earnings Season?

Investors are always looking for stocks that are poised to beat at earnings season and Pliant The...

Zacks via Yahoo Finance 10 Nov 2023

Pliant Therapeutics, Inc. (PLRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3...

Wall Street expects a year-over-year decline in earnings on higher revenues when Pliant Therapeut...

Zacks via Yahoo Finance 7 Nov 2023

Pliant (PLRX) Up on Success of Mid-Stage Liver Disease Study

Shares of Pliant Therapeutics, Inc. PLRX gained 14.3% on Sep 26 after the company announced that ...

Zacks · via Yahoo Finance 27 Oct 2023

Investors in Pliant Therapeutics (NASDAQ:PLRX) have seen splendid returns of...

While Pliant Therapeutics, Inc. (NASDAQ:PLRX) shareholders are probably generally happy, the stoc...

Simply Wall St. · via Yahoo Finance 22 Oct 2023

Pliant Therapeutics, Inc. (PLRX) Soars 14.3%: Is Further Upside Left in the...

Pliant Therapeutics, Inc. PLRX shares ended the last trading session 14.3% higher at $16.67. The ...

Zacks · via Yahoo Finance 22 Oct 2023

Pliant Therapeutics, Inc. (PLRX) Reports Q2 Loss, Misses Revenue Estimates

Pliant Therapeutics, Inc. (PLRX) came out with a quarterly loss of $0.70 per share versus the Zac...

Zacks via Yahoo Finance 10 Aug 2023

Pliant Therapeutics, Inc. (PLRX) Reports Q1 Loss, Misses Revenue Estimates

Pliant Therapeutics, Inc. (PLRX) came out with a quarterly loss of $0.67 per share versus the Zac...

Zacks via Yahoo Finance 10 May 2023